Please login to the form below

No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer

The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer.


Summary/transcript

The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer.

We talked to Dr Ursula Matulonis of the Dana-Farber Cancer Institute, who co-authored the abstract presented at ESMO. She explains that the women on the trial underwent germline BRCA testing and were grouped into gBRCA and non-gBRCA cohort; in the latter cohort, they were further tested for homologous recombination deficiency (HRD).

In all the groups, there was a benefit to receiving niraparib and this is not a surprising result as Dr Matulonis explains, as all the patients with epithelial ovarian cancer were distilled “into the group that’s going to benefit most from a PARP inhibitor”. She highlights that the results are very exciting and that “it is the first Phase III trial to be reported of a PARP inhibitor and showing really quite significant progression-free survival benefit”.

If you would like to discover how we can leverage our network of relationships and understanding of the oncology landscape and stakeholders, to shape content and amplify messages across relevant audiences, channels and communities please contact Stephen Dunn or Charlie Grieve on 020 7291 5070, we’d be delighted to hear from you.

17th November 2016

Share

Tags

Company Details

Brandcast Health

+44 (0)20 7291 5070

Contact Website

Address:
16-17 Little Portland Street
London
W1W 8BP

Latest content on this profile

Ansar Jawair discusses precision medicines - what they are, where we are today and their future
Ansar Jawair, Founder and CEO of Precision Medicines Ltd, tells us about his talk on precision medicines, what they are, where we are today, the future and some of the challenges involved in their implementation to patients. Precision medicines are matched to patients using biomarkers, enabling to target the specific drivers of various cancers. Major advances have already been made in this field, treating a range of cancers. Some of the major challenges include working with the complexities in different countries, trying to establish diagnostic testing, for enabling precision medicine. He mentions how we are moving towards an era of delivering personalised treatments that are matched to the individual patient. Furthermore, through advances in precision medicines and in diagnostic testing, we are seeing earlier detection of disease and identification of risk factors, allowing for preventative measures.
Brandcast Health
Oradit Ido talks about the Unique Israeli Entrepreneurial Ecosystem
Orado provides an overview of why she believes Israel is unique in its approach to innovation. With a history of overcoming challenges, a people who pride themselves on their chutzpe (audaciousness), and a fast paced culture, she explains why she thinks Israel provides a perfect ecosystem for innovation and entrepreneurship. She explains that within medicine and healthcare, there is a need for strategic support and engagement, and as an example of how the government is supporting this she provides an overview of the Ministry of Health challenge tender programme.
Brandcast Health
Acute leukaemia patients get new online information centre that will help them get the best possible care
A unique collaboration between some of the world's leading leukaemia experts and the patient community in the UK and across Europe has resulted in the development of a one-of-a-kind educational resource centre that provides acute leukaemia patients with the support they need, when they need it most. It is the first time that such a comprehensive medical information video resource has been gathered together in this format and comes at a time when cancer patients and caregivers are advocating for a bigger say in decisions about their individual treatment regimens.
Brandcast Health
Aubrey De Grey provides a summary of his goal of combating ageing
Aubrey believes ageing is a serious issue, not only because people die of old age, but because it causes suffering. He discusses the fact that many diseases including chronic cancer, are the result of ageing and that by tackling ageing of cells, we can address many of the issues associated with poor health. To find out more about Aubrey and the SENS Research Foundation visit: http://www.sens.org/
Brandcast Health
Oradit Ido talks about the Unique Israeli Entrepreneurial Ecosystem
Orado provides an overview of why she believes Israel is unique in its approach to innovation. With a history of overcoming challenges, a people who pride themselves on their chutzpe (audaciousness), and a fast paced culture, she explains why she thinks Israel provides a perfect ecosystem for innovation and entrepreneurship. She explains that within medicine and healthcare, there is a need for strategic support and engagement, and as an example of how the government is supporting this she provides an overview of the Ministry of Health challenge tender programme.
Brandcast Health
HaemOncCam #Haem2016

Brandcast Health